According to NBD AI news, an investor asked on the investor interaction platform: As the flu season approaches, does your company have sales of flu-related medications？

Xidian Pharmaceutical (301130.SZ) stated on the platform on November 19th that regarding its existing marketed products, our company has a mature anti-influenza drug-- Compound Paracetamol and Analgin Capsule, and an antiviral tablet that will be approved for market in 2025 and is clinically used for treating upper respiratory tract infections and influenza. The company's ongoing research project "Study on the Intervention Effect of daphnetin on Mice Models of Human Diseases " has sub-project "Research on the Intervention Effect of daphnetin on Mouse Virus Pneumonia Models", in which the experimental results showing the safety and effectiveness of rixinzhi in treating viral pneumonia have been obtained. We have also obtained the invention patent "Application of daphnetin in the Preparation of Drugs for Treating Viral Pneumonia". If there are substantive progress in capital operation, we will strictly fulfill the information disclosure obligations in accordance with relevant regulations.

https://finance.eastmoney.com/a/202511193568593192.html